A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure

NCT02342379 Phase 2 COMPLETED Results posted

Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.

Details

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	Phase 2
Status	COMPLETED
Enrolment	35
Start date	2015-05
Completion	2019-12-04

Conditions

• Glioblastoma

Interventions

• Bevacizumab
• TH-302

Primary outcomes

• Number of Patients With Adverse Events — 4 months
  Safety lab tests and adverse event assessment

Countries

United States